SENP5 and osteosarcoma: On the other hand, SENP5 has oncogenic activity in osteosarcoma, both in patients’ primary cancer cells and in cell lines, where this SUMO protease is overexpressed, resulting in resistance to both apoptosis and arrest of the cell cycle.